Morgan Stanley also reaffirmed an Overweight rating with a price target of $1,133, following a new agreement with Cigna/Evernorth to cap patient copays for Eli Lilly’s Zepbound.

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk. The full data from the 751-subject SURMOUNT-5 ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...

Entering text into the input field will update the search result below Home page Seeking Alpha - Power to Investors Search for Symbols, analysts, keywords ...